LT4758B - Pramoniniai gaminiai - Google Patents

Pramoniniai gaminiai Download PDF

Info

Publication number
LT4758B
LT4758B LT2000035A LT2000035A LT4758B LT 4758 B LT4758 B LT 4758B LT 2000035 A LT2000035 A LT 2000035A LT 2000035 A LT2000035 A LT 2000035A LT 4758 B LT4758 B LT 4758B
Authority
LT
Lithuania
Prior art keywords
pde5
treatment
pde5 inhibitor
sexual dysfunction
inhibition
Prior art date
Application number
LT2000035A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000035A (lt
Inventor
Jeffrey Thomas Emmick
William Ernest Pullman
Kenneth Michael Ferguson
John Steven Whitaker
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4758(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of LT2000035A publication Critical patent/LT2000035A/xx
Publication of LT4758B publication Critical patent/LT4758B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
LT2000035A 1999-04-30 2000-04-26 Pramoniniai gaminiai LT4758B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (2)

Publication Number Publication Date
LT2000035A LT2000035A (lt) 2000-11-27
LT4758B true LT4758B (lt) 2001-02-26

Family

ID=22452153

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000035A LT4758B (lt) 1999-04-30 2000-04-26 Pramoniniai gaminiai

Country Status (47)

Country Link
EP (2) EP1173181B3 (es)
JP (2) JP2000336043A (es)
KR (2) KR20010020779A (es)
CN (2) CN1292264A (es)
AT (1) ATE251908T1 (es)
AU (3) AU769946C (es)
BE (1) BE1012957A5 (es)
BR (2) BR0010181A (es)
CA (2) CA2307101C (es)
CH (2) CH692478A5 (es)
CO (1) CO5170493A1 (es)
CZ (1) CZ296534B6 (es)
DE (3) DE60005940T3 (es)
DK (2) DK1173181T6 (es)
DZ (1) DZ3171A1 (es)
EA (2) EA005416B1 (es)
ES (2) ES2187234A1 (es)
FI (1) FI20000976A7 (es)
FR (1) FR2795646B1 (es)
GB (1) GB2351663A (es)
GR (1) GR1003575B (es)
HK (1) HK1041204B (es)
HR (2) HRP20010778B1 (es)
HU (2) HUP0001632A3 (es)
ID (1) ID25704A (es)
IE (1) IE20000315A1 (es)
IL (3) IL135817A0 (es)
IT (1) ITMI20000922A1 (es)
LT (1) LT4758B (es)
LU (1) LU90569B1 (es)
LV (1) LV12560B (es)
MX (2) MXPA00003997A (es)
NL (1) NL1015027C2 (es)
NO (2) NO20002097L (es)
NZ (2) NZ504163A (es)
PE (1) PE20010071A1 (es)
PL (2) PL339897A1 (es)
PT (2) PT1173181E (es)
SE (1) SE0001518L (es)
SG (1) SG98384A1 (es)
SI (2) SI1173181T1 (es)
SK (1) SK285415B6 (es)
SV (1) SV2002000055A (es)
TR (1) TR200001132A2 (es)
UA (1) UA72248C2 (es)
WO (1) WO2000066099A2 (es)
ZA (2) ZA200002058B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516616A (en) * 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
WO2002010166A1 (en) * 2000-08-02 2002-02-07 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
EP1401449B1 (en) * 2001-06-05 2007-04-25 Lilly Icos LLC Tetracyclic compounds as pde5-inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
AU2007230716B2 (en) * 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
KR102894055B1 (ko) * 2018-02-07 2025-12-02 스마와 게엠베하 약학 제형, 약학 제형을 제조하기 위한 방법 및 이를 포함하는 의약

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
US5859006A (en) 1994-01-21 1999-01-12 Icos Corporation Tetracyclic derivatives; process of preparation and use
US5981527A (en) 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6001847A (en) 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
SK285991B6 (sk) * 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000020033A1 (en) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
CA2365782A1 (en) * 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859006A (en) 1994-01-21 1999-01-12 Icos Corporation Tetracyclic derivatives; process of preparation and use
US5981527A (en) 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6001847A (en) 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOOLELL M ET AL.: "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction", INT J IMPOT RES., 1996, pages 47 - 52, XP000938747
CHENG Y, PRUSOFF WH.: "Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.", BIOCHEM PHARMACOL., 1973, pages 3099 - 3108, XP001106687, DOI: doi:10.1016/0006-2952(73)90196-2
CONTI, R.C ET AL.: "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease", AMERICAN JOURNAL OF CARDIOLOGY, 1999, pages 29 - 34
MURRAY K.J.: "Phosphodiesterase VA inhibitors.", DRUG NEWS & PERSPECTIVES, 1993, pages 150 - 156, XP002924954
WEBB, D.J ET AL.: "Sildenafil Citrate and blood pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist", AMERICAN JOURNAL OF CARDIOLOGY, 1999, pages 21 - 28

Also Published As

Publication number Publication date
BE1012957A5 (fr) 2001-06-05
CA2307101C (en) 2003-01-28
CA2307101A1 (en) 2000-10-30
AU769946C (en) 2005-01-13
NL1015027C2 (nl) 2001-02-14
HUP0001632A3 (en) 2001-12-28
GR1003575B (el) 2001-05-14
MXPA00003997A (es) 2002-03-08
HUP0001632A2 (hu) 2001-05-28
IL135817A0 (en) 2001-05-20
NO20015275L (no) 2001-12-06
HRP20010778B1 (en) 2005-04-30
AU3012900A (en) 2000-11-02
NO20002097D0 (no) 2000-04-25
WO2000066099A3 (en) 2001-01-18
JP2000336043A (ja) 2000-12-05
SE0001518L (sv) 2000-10-31
PL352629A1 (en) 2003-08-25
EA200000355A2 (ru) 2000-10-30
DK200000677A (da) 2000-10-31
NZ514882A (en) 2003-08-29
JP2002543116A (ja) 2002-12-17
KR100577057B1 (ko) 2006-05-10
WO2000066099A2 (en) 2000-11-09
EP1173181B1 (en) 2003-10-15
DE20007861U1 (de) 2000-08-24
ID25704A (id) 2000-11-02
CA2371684C (en) 2007-10-23
DE10021266A1 (de) 2000-11-16
SV2002000055A (es) 2002-07-03
KR20010020779A (ko) 2001-03-15
TR200001132A3 (tr) 2001-01-22
SI20361A (sl) 2001-04-30
IL146098A (en) 2007-06-03
LV12560B (en) 2001-04-20
HUP0200912A2 (en) 2002-08-28
ATE251908T1 (de) 2003-11-15
HUP0200912A3 (en) 2003-07-28
GB0010199D0 (en) 2000-06-14
IE20000315A1 (en) 2001-03-07
BR0010181A (pt) 2003-02-25
ES2208317T3 (es) 2004-06-16
UA72248C2 (en) 2005-02-15
FR2795646A1 (fr) 2001-01-05
IL146098A0 (en) 2002-07-25
HRP20000243A2 (en) 2001-12-31
SE0001518D0 (sv) 2000-04-26
ITMI20000922A1 (it) 2001-10-26
SG98384A1 (en) 2003-09-19
SK15632001A3 (sk) 2002-02-05
LU90569B1 (fr) 2002-02-27
CZ296534B6 (cs) 2006-04-12
BR0003046A (pt) 2002-07-23
JP4975214B2 (ja) 2012-07-11
AU769946B2 (en) 2004-02-12
TR200001132A2 (tr) 2001-01-22
DE60005940T3 (de) 2015-08-27
AU2004201988A1 (en) 2004-06-10
EP1415652A3 (en) 2004-05-12
CN1292264A (zh) 2001-04-25
SI1173181T1 (en) 2004-04-30
MXPA01010837A (es) 2002-11-07
HU230369B1 (hu) 2016-03-29
AU4490800A (en) 2000-11-17
SK285415B6 (sk) 2007-01-04
ES2208317T7 (es) 2015-09-15
PT1173181E (pt) 2004-02-27
FI20000976L (fi) 2000-10-30
CH1173181H1 (es) 2019-07-15
DE60005940T2 (de) 2004-07-29
NO20002097L (no) 2001-10-26
EP1415652A2 (en) 2004-05-06
GR20000100153A (el) 2000-12-29
HU0200912D0 (en) 2002-04-29
FI20000976A0 (fi) 2000-04-26
NZ504163A (en) 2001-11-30
DZ3171A1 (es) 2000-11-09
CH692478A5 (de) 2002-07-15
PL197813B1 (pl) 2008-04-30
DK1173181T6 (en) 2015-04-27
PT102457A (pt) 2000-11-30
CO5170493A1 (es) 2002-06-27
KR20020008396A (ko) 2002-01-30
CN1196487C (zh) 2005-04-13
CN1384746A (zh) 2002-12-11
PL339897A1 (en) 2000-11-06
HK1041204B (en) 2004-03-05
ZA200108900B (en) 2003-03-26
CZ20013879A3 (cs) 2002-04-17
LT2000035A (lt) 2000-11-27
EP1173181B3 (en) 2015-03-25
EA200000355A3 (ru) 2001-02-26
NL1015027A1 (nl) 2000-10-31
PE20010071A1 (es) 2001-03-22
GB2351663A (en) 2001-01-10
FR2795646B1 (fr) 2002-08-16
ZA200002058B (en) 2000-11-02
EA200101008A1 (ru) 2002-04-25
FI20000976A7 (fi) 2000-10-30
LV12560A (en) 2000-11-20
NO322013B3 (no) 2017-11-06
DE60005940D1 (de) 2003-11-20
ITMI20000922A0 (it) 2000-04-26
CA2371684A1 (en) 2000-11-09
DK1173181T3 (da) 2004-02-16
NO20015275D0 (no) 2001-10-29
EP1173181A2 (en) 2002-01-23
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
ES2187234A1 (es) 2003-05-16
NO322013B1 (no) 2006-08-07

Similar Documents

Publication Publication Date Title
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
EP1173181B1 (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
CZ20001536A3 (cs) Orální léčivo
HK1065485A (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20040426